September 1, 2010 – 5:00 am
BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 – 9:00 AM podium presentation session… (Source: Health News from Medical News Today)
September 1, 2010 – 2:00 am
Atrial Fibrillation (A Fib) a type of heart rhythm disorder that affects the electrical system, or “wiring,” of the heart muscle is often referred to as the “silent killer,” and can suddenly trigger a massive, debilitating stroke or even death. During September National Atrial Fibrillation Awareness Month physicians at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center are working to raise awareness about life-changing treatment options, and even cures, for this potentially fatal condition… (Source: Health News from Medical News Today)
September 1, 2010 – 1:00 am
MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, today announced that its partner, Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc (LSE: RB), has received approval from the U.S. Food and Drug Administration (FDA) to market Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for the treatment of opioid dependence. This is the second U.S… (Source: Health News from Medical News Today)
September 1, 2010 – 1:00 am
Glenmark Pharmaceuticals announced the discovery of a Novel Chemical Entity(NCE) ‘GRC 17536′. The new NCE program is targeting TRPA1 receptor antagonists for pain and respiratory disorders. TRPA1 belongs to Transient Receptor Potential (TRP) family of ion channels, which have generated a lot of interest as pain targets due to their distinguishing role in peripheral and/or central pain signal transmission. Glenmark has selected a lead molecule named GRC 17536 which is currently finishing up Phase 1 enabling GLP studies… (Source: Health News from Medical News Today)
September 1, 2010 – 1:00 am
QRxPharma (ASX: QRX and OTCQX: QRXPY) announced it will sponsor a symposium at the 13th World Congress of Pain on 31 August, 2010 at Palais des congres de Montreal. The symposium, titled “Dual Opioid Therapy: Changing the Paradigm” will focus on preclinical and clinical data for MoxDuo®IR, an immediate-release Dual Opioid product for moderate to severe acute pain. Featured speakers who will highlight Dual Opioids at this symposium are internationally recognised pain experts, Drs. Nicholson, Pasternak and Webster… (Source: Health News from Medical News Today)
September 1, 2010 – 12:00 am
Texans seeking pain relief soon can take comfort from a new state law requiring pain management clinics to be certified by the Texas Medical Board (TMB) by Sept. 1. Texas physicians hope the new law will put “pill mills,” storefronts disguised as pain medicine clinics, out of commission. These storefronts skirt the patient-physician relationship by providing powerful narcotic prescriptions without requiring a patient exam, explains Texas Medicine magazine, the official publication of the Texas Medical Association (TMA)… (Source: Health News from Medical News Today)
August 30, 2010 – 8:00 am
For patients with chronic (long-term) neuropathic pain, smoking cannabis was found to reduce symptoms of pain, improve mood and help sleep, a report published in CMAJ (Canadian Medical Journal Association) revealed. When damage or dysfunction of the nervous system results in chronic neuropathic pain, patients have few treatment options, such as antidepressants, local anesthetics, anticonvulsants or opioids. However, these medications often have undesirable side effects and do not work for everybody… (Source: Health News from Medical News Today)
August 30, 2010 – 3:00 am
Hospira Japan Co., Ltd. announced it has received an approval for the long-term (greater than 24 hour) use of the sedative “Precedex IV(TM)200ug” (generic name: dexmedetomidine hydrochloride). This approval follows Hospira’s first launches earlier this year of Precedex in Canada and in South Korea, important milestones for Hospira as the company continues to build the molecule’s global presence. Originally, Precedex was approved in Japan in 2004 for sedation of initially intubated and mechanically ventilated patients in the intensive care setting for use up to 24 hours… (Source: Health News from Medical News Today)
August 30, 2010 – 12:00 am
Despite the fact that an estimated 25 million patients per year in the U.S. undergo surgeries using general anesthesia, scientists have only been able to hypothesize exactly how anesthetics interact with the central nervous system. They previously thought that the processes of “going under” and waking up from anesthesia affected the brain in the same way. Now, researchers at the University of Pennsylvania School of Medicine have established in animal models that the brain comes in and out of a state of induced unconsciousness through different processes… (Source: Health News from Medical News Today)
August 28, 2010 – 12:00 am
The American Pain Foundation (APF), the nation’s largest consumer advocacy organization for people in pain, released a position statement imploring the medical community, regulators and concerned stakeholders to reaffirm their ethical commitment to the 76.5 million Americans or one in four people who struggle with pain, work collaboratively to improve access to pain care and dismantle the barriers preventing timely, appropriate and effective pain care for millions… (Source: Health News from Medical News Today)
Subscribe to feed